Peanut Market

View All

Pharma News
First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed’s shares Soares

The US FDA has given its recommendation to the Aimmune Therapeutics’ drug, Palforzia, the first-ever treatment for Peanut Allergy. Palforzia is an oral immunotherapy, set to address the unmet needs in the Peanut market, reducing the incidence and severity of allergic reactions, including anaphylaxis, which may ...

Find More